Authors: | Santini, F. C.; Salhab, R. M.; Sharma, S.; Drilon, A. |
Article Title: | Expanding the portfolio of anaplastic lymphoma kinase inhibitors for anaplastic lymphoma kinase-rearranged lung cancers |
Keywords: | cancer survival; treatment response; overall survival; constipation; fatigue; neutropenia; diarrhea; drug efficacy; hypertension; side effect; unspecified side effect; edema; progression free survival; gastrointestinal symptom; lung disease; nausea; vomiting; lung cancer; editorial; dyspnea; pneumonia; oncogene; drug fatality; gene rearrangement; brain metastasis; peripheral edema; interstitial lung disease; creatine kinase; aminotransferase; pemetrexed; visual disorder; triacylglycerol lipase; non small cell lung cancer; anaplastic lymphoma kinase; randomized controlled trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); hypertransaminasemia; crizotinib; alk gene; human; ceritinib; alectinib; anaplastic lymphoma kinase inhibitor; brigatinib; lorlatinib |
Journal Title: | Translational Cancer Research |
Volume: | 6 |
Issue: | Suppl. 9 |
ISSN: | 2218-676X |
Publisher: | Pioneer Bioscience Publishing Company |
Date Published: | 2017-12-01 |
Start Page: | S1418 |
End Page: | S1421 |
Language: | English |
DOI: | 10.21037/tcr.2017.10.42 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | Editorial -- Export Date: 2 January 2018 -- Source: Scopus |